Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors.

Cell communication and signaling : CCS - 21 Nov 2024

Delyon Julie, Becherirat Selma, Roger Anissa, Bernard-Cacciarella Mélanie, Reger De Moura Coralie, Louveau Baptiste, Mourah Samia, Lebbé Céleste, Dumaz Nicolas

Abstract excerpt

BACKGROUND: Phosphodiesterase type 4D (PDE4D) breaks down cyclic AMP (cAMP) reducing the signaling of this intracellular second messenger which plays a major role in melanocyte pathophysiology. In advanced melanoma, expression of PDE4D is increased, plays a role in tumor invasion and is negatively associated with survival. In the current work, we investigated the role of PDE4D in the resistance of BRAF-mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cyclic Nucleotide Phosphodiesterases, Type 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to Drug Resistance, Neoplasm

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 39574163
DOI: 10.1186/s12964-024-01941-y
PMCID: PMC11580363

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors.PMID 39574163Read ↗

PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.Semantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma.Semantic proximity Read ↗

Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells.Semantic proximity Read ↗

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITFSemantic proximity Read ↗

Dual Specificity Phosphatase 1 (DUSP1) Provides Mechanistic Link Between Melanoma Cellular Plasticity and Drug ResistanceSemantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.Semantic proximity Read ↗

The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.Semantic proximity Read ↗

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.Semantic proximity Read ↗

Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.